#CancerMoonshot today will not only be about glioblastoma, but about the horrible DIPG (diffuse intrinsic pontine glioma) occuring in children and young adults.
You know who got their PIP plan approved last year by the MHRA in the UK?
You know who ANNOUNCED a new center of cancer excellence in Sutton in the UK two months ago, 130 miles from Sawston, focusing on DIPG?
You know who donated 2.5 million pounds to the center and that Hugh Adams works for them and have helped NWBO meeting british politicians and he wrote the "Pathway to a Cure" report, where politicians urges MHRA and NICE to get DCVax-L to patients?
SAME DAY MHRA announced this
"This new funding will accelerate the delivery of cutting-edge treatments like cancer vaccines"
One week later the MHRA announced this.
The new Quarterly SEC filing says
"We plan to work on preparations for Phase II trials of DCVax-Direct as resources permit."
You know NWBO already had planned DCVax-Direct trials in 2019 targeting DIPG?
With the help of @d_stock07734's due diligence, it seems like we are able to uncover what must have been quite a challenge at that time for Masaryk University.
The manufactoring of the dendritic cell vaccine for the trial.
Please follow @d_stock07734 for additional due diligence regarding the Czech Trial results and other possible links.
In 2014, Masaryk University launched a pediatric trial using a dendritic cell vaccine called MyDendrix to treat children with metastatic/refractory tumors.
The methods looked strikingly familiar to NWBO’s DCVax-L platform.
Allow me to entertain a hypothesis, that is probable "far out", but which I somehow still find believable, knowing Linda Powers setup several dormant companies in 2014, obviously trying to predict a few chess board moves over the last decade.
Let's say she did that.
1/
Something extraordinary may have just come together for NWBO - and many missed it.
A Czech trial, once unrelated, now bears the name Murcidencel - the official WHO name for NWBO’s DCVax-L.
Coincidence?
ChatGPT and Perplexity says otherwise.
2/
In 2022, the WHO approved Murcidencel as the INN for NWBO’s DCVax-L.
This isn’t a marketing term - it’s an internationally protected name that defines the therapy's composition:
autologous dendritic cells, tumor lysate, matured with GM-CSF and IL-4.
Laura Posner (Cohen Milstein) & Columbia law prof Joshua Mitts filed a powerful amicus brief in Slack v. Pirani, arguing that modern tech makes it possible to trace stock origins—a key issue in securities fraud.
In the case, the Supreme Court ruled that if you sue under Section 11 of the Securities Act, you must prove your shares came from the registration statement you’re challenging.
That’s called traceability
3/
Critics said this would block investors from suing, especially in direct listings where shares are mixed.
But Posner & Mitts argued: with today’s digital trading records, we can trace shares.